Matthew Pauls Sells 5,937 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) Stock

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Director Matthew Pauls sold 5,937 shares of the company’s stock in a transaction dated Friday, March 28th. The stock was sold at an average price of $71.55, for a total value of $424,792.35. Following the completion of the transaction, the director now directly owns 6,500 shares of the company’s stock, valued at $465,075. The trade was a 47.74 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Soleno Therapeutics Price Performance

NASDAQ:SLNO opened at $68.26 on Wednesday. The company’s 50-day moving average is $49.82 and its two-hundred day moving average is $50.34. Soleno Therapeutics, Inc. has a 1-year low of $36.61 and a 1-year high of $73.97. The firm has a market capitalization of $3.13 billion, a price-to-earnings ratio of -20.56 and a beta of -1.70.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.41). As a group, equities analysts anticipate that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Soleno Therapeutics

A number of hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC raised its holdings in Soleno Therapeutics by 27.1% in the 4th quarter. Janus Henderson Group PLC now owns 5,188,265 shares of the company’s stock valued at $233,130,000 after buying an additional 1,107,166 shares during the period. Nantahala Capital Management LLC lifted its holdings in shares of Soleno Therapeutics by 20.1% in the 4th quarter. Nantahala Capital Management LLC now owns 3,928,966 shares of the company’s stock worth $176,607,000 after acquiring an additional 658,518 shares during the last quarter. Avoro Capital Advisors LLC lifted its holdings in shares of Soleno Therapeutics by 15.8% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,525,000 shares of the company’s stock worth $113,499,000 after acquiring an additional 344,000 shares during the last quarter. Vanguard Group Inc. increased its holdings in Soleno Therapeutics by 19.2% in the 4th quarter. Vanguard Group Inc. now owns 1,884,533 shares of the company’s stock valued at $84,710,000 after purchasing an additional 303,806 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in Soleno Therapeutics by 24.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,630,718 shares of the company’s stock valued at $73,301,000 after purchasing an additional 321,223 shares during the period. 97.42% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

SLNO has been the topic of several research reports. Robert W. Baird raised their target price on Soleno Therapeutics from $72.00 to $102.00 and gave the company an “outperform” rating in a research report on Thursday, March 27th. Guggenheim reaffirmed a “buy” rating and set a $81.00 target price (up previously from $70.00) on shares of Soleno Therapeutics in a research note on Friday. Stifel Nicolaus increased their target price on shares of Soleno Therapeutics from $74.00 to $108.00 and gave the company a “buy” rating in a research report on Friday, March 28th. Lifesci Capital upgraded shares of Soleno Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 4th. Finally, Cantor Fitzgerald increased their price objective on shares of Soleno Therapeutics from $67.00 to $123.00 and gave the company an “overweight” rating in a report on Thursday, March 27th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Soleno Therapeutics has a consensus rating of “Buy” and a consensus price target of $98.86.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.